AML Video Channel
Explore the latest insights and summaries from experts in AML.
Recommended for You
Loading...
Trending Videos This Week
Loading...
Treatment Landscape
University of Colorado Division of Hematology
2024 Updates in AML
FEATURING
Christine McMahon
- 751 views
- April 16, 2024
- 6
Insights from 2024 EHA Annual Meeting
AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024
FEATURING
Talha Badar
- 725 views
- July 16, 2024
- 4
Rush University Medical Center
Is Post-HSCT Maintenance the SOC for AML?
FEATURING
Mark Levis
- 302 views
- May 29, 2024
- 4
Indy Hematology Review
Treatment of AML: Managing the Patient When Transplant Is Not an Option
FEATURING
Harry P. Erba
- 898 views
- April 17, 2024
- 7
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
The Truth About Current Consensus Statements on Hematopoietic Cell Transplant
FEATURING
Robert Peter Gale
- 520 views
- February 15, 2024
- 2
Insights from 2023 ASH Annual Meeting
AML and MDS Highlights & Key Takeaways
FEATURING
Talha Badar
- 2,207 views
- January 24, 2024
- 14
SOHO Brazil 2024
Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde
FEATURING
Jeffrey Lancet
- 530 views
- July 11, 2024
- 2
MyCancerHaven
Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPDCN
FEATURING
Ravi Vij,
Guru Murthy
- 608 views
- August 30, 2024
- 3
Icahn School of Medicine at Mount Sinai
Integrating Targeted Therapies in AML
FEATURING
Hagop Kantarjian
- 423 views
- May 31, 2024
- 3
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 488 views
- May 31, 2024
- 2
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 350 views
- April 22, 2024
- 3
Memorial Sloan Kettering Cancer Center
Key Updates in AML, MDS, & MF From ASH
FEATURING
Aaron Goldberg
- 300 views
- May 2, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger Patients With AML - Intensive vs. Non-Intensive Approaches"
FEATURING
Christine McMahon
- 292 views
- June 20, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
FEATURING
Tapan Kadia
- 673 views
- September 11, 2024
- 7
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 384 views
- March 25, 2024
- 2
Rush University Medical Center
Allo-HSCT Conditioning Regimens: Current Status and Future Directions
FEATURING
Claudio Brunstein
- 264 views
- May 24, 2024
UChicago Medicine
AML: Current Treatment Landscape and Key Recent Updates
FEATURING
Anand Patel
- 384 views
- March 20, 2024
- 3
Vanderbilt University Medical Center (VUMC)
Prevention and Management of Post-SCT Relapse in Acute Leukemias
FEATURING
Andrew Jallouk
- 257 views
- July 18, 2024
- 6
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
State of the Art: Role of Maintenance Therapy in AML
FEATURING
Zeba Aziz
- 230 views
- February 15, 2024
2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Summary: Highlights in Heme Malignancies
FEATURING
Maria Gomes da Silva
- 456 views
- September 23, 2024
- 2
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 536 views
- March 11, 2024
- 3
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 240 views
- July 8, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of AML in Older Patients
FEATURING
Farhad Ravandi
- 199 views
- August 29, 2024
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 231 views
- May 29, 2024
- 1
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 132 views
- August 26, 2024
MyCancerHaven
Updates in Frontline Treatment of Fit Patients With AML
FEATURING
Ravi Vij,
Manuel Espinoza Gutarra
- 106 views
- April 30, 2024
MyCancerHaven
Experts Discuss the Role of Stem Cell Transplant in AML
FEATURING
Ravi Vij,
Muzaffar Qazilbash
- 114 views
- April 11, 2024
- 1
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Scripps Health
Managing Intensive-Chemotherapy Ineligible Patients With AML
FEATURING
Courtney D. DiNardo
- 161 views
- March 20, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Art and Science of Caring for Older Adults With Myeloid Malignancies"
FEATURING
Kah Poh Loh
- 96 views
- June 16, 2024
Talha Badar
Challenges in the Management of TP53-Mutated AML: Potential Strategies to Improve Outcomes
- 452 views
- March 5, 2024
- 3
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 141 views
- May 3, 2024
Vanderbilt University Medical Center (VUMC)
Pre-Transplant Management of High-Risk AML
FEATURING
Kateryna Fedorov
- 97 views
- July 18, 2024
- 2
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Acute Promyelocytic Leukemia: Risk Stratification and New Treatment Modalities
FEATURING
Suar ÇAkı Kılıç
- 83 views
- February 16, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Febrile Neutropenia in Patients With Cancer
FEATURING
Şiran Keske
- 65 views
- February 21, 2024
- 1
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 3+7 is the SOC Induction Therapy for AML
FEATURING
Ant Uzay
- 56 views
- August 15, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
A 50-Year Personal Perspective on the Treatment of AML
FEATURING
Charles A. Schiffer
- 167 views
- February 21, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Future Directions in AML: Optimizing Doublets and Triplets to Improve Efficacy and Maintain Safety
FEATURING
Naval Daver
- 58 views
- February 15, 2024
Therapeutic Agents
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Emerging Treatment Options for AML in 2024
FEATURING
Alexander Perl
- 723 views
- March 3, 2024
- 4
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 350 views
- April 22, 2024
- 3
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Immunotherapies in Acute Leukemias: 2024 Update
FEATURING
Catherine Lai
- 536 views
- March 11, 2024
- 3
SOHO Brazil 2024
Where I Use Azacitidine and Venetoclax in AML: Present and Future
FEATURING
Jeffrey Lancet
- 469 views
- July 11, 2024
- 4
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 488 views
- May 31, 2024
- 2
Rush University Medical Center
Management of Viral Infections Post-Transplant: CMV, EBV, and HHV-6
FEATURING
Eric Bhaimia
- 339 views
- May 24, 2024
Indy Hematology Review
HSCT in 2024: What Every Hematologist Needs to Know
FEATURING
Richard Childs
- 750 views
- April 18, 2024
- 5
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 907 views
- April 16, 2024
- 5
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
FEATURING
Hany Elmariah
- 329 views
- March 7, 2024
- 5
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
FEATURING
Tapan Kadia
- 673 views
- September 11, 2024
- 7
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 384 views
- March 25, 2024
- 2
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-IDA + Venetoclax in Newly Diagnosed or R/R AML
FEATURING
Wei-Ying Jen
- 246 views
- June 26, 2024
- 2
University of Miami Sylvester Comprehensive Cancer Center
Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis but is Actionable
FEATURING
Sangeetha Venugopal
- 185 views
- March 18, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: FLAG-GO vs. FLAG-IDA in Untreated Core Binding Factor AML
FEATURING
Gautam Borthakur
- 150 views
- July 1, 2024
- 2
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of AML in Older Patients
FEATURING
Farhad Ravandi
- 199 views
- August 29, 2024
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 231 views
- May 29, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagraxofusp
FEATURING
Emanuele Angelucci
- 216 views
- July 23, 2024
- 1
SOHO Brazil 2024
The Gold Standard in the Use of FLT3 and IDH Inhibitors in AML
FEATURING
Jeffrey Lancet
- 136 views
- July 11, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ AML Patients Receiving Chemo + Quizartinib vs. Placebo
FEATURING
Esther Oliva
- 129 views
- June 28, 2024
Yale Cancer Center
The Role of Hypomethylating Agent Maintenance in AML
FEATURING
Rory Shallis
- 117 views
- July 1, 2024
University of Miami Sylvester Comprehensive Cancer Center
Current and Emerging Treatment Approaches for Patients With AML or MDS
FEATURING
Sangeetha Venugopal
- 132 views
- August 26, 2024
Insights from 2023 ASH Annual Meeting
FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartinib vs. Standard Chemo
FEATURING
Esther Oliva
- 152 views
- March 22, 2024
MyCancerHaven
Experts Discuss the Role of Stem Cell Transplant in AML
FEATURING
Ravi Vij,
Muzaffar Qazilbash
- 114 views
- April 11, 2024
- 1
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Scripps Health
Managing Intensive-Chemotherapy Ineligible Patients With AML
FEATURING
Courtney D. DiNardo
- 161 views
- March 20, 2024
- 2
Yale Cancer Center
Summary of Promising Recent Studies in LR-MDS, HR-MDS, and R/R AML
FEATURING
Rory Shallis
- 91 views
- May 16, 2024
ecancer
EHA 2024 Insights: APOLLO Trial Summary - ATRA + ATO vs. Standard ATRA + Chemo in High-Risk APL
FEATURING
Uwe Platzbecker
- 92 views
- July 24, 2024
Indy Hematology Review
Current & Emerging Therapies for AML and MDS
FEATURING
Rami Komrokji
- 141 views
- May 3, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: QUAZAR AML-001 - Oral Azacitidine Maintenance in AML Pts With Myelodysplasia-Related Changes
FEATURING
Maria Teresa Voso
- 87 views
- June 20, 2024
Yale Cancer Center
Targeting Apoptosis in Leukemia: Lessons and Challenges
FEATURING
Marina Konopleva
- 110 views
- March 15, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: AML Highlights - Focus on Menin Inhibitors
FEATURING
Joshua Zeidner
- 68 views
- June 26, 2024
Icahn School of Medicine at Mount Sinai
Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias
FEATURING
Omar Abdel-Wahab
- 57 views
- July 2, 2024
UNC Lineberger Comprehensive Cancer Center
Strategies for Managing Toxicities of Oral Oncolytics in Leukemia
- 57 views
- August 28, 2024
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 3+7 is the SOC Induction Therapy for AML
FEATURING
Ant Uzay
- 56 views
- August 15, 2024
- 1
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 146 views
- February 27, 2024
- 2
Louisville Hematology Highlights
Is a Bigger Induction "Hammer" Necessarily Better in Today's Stem Cell Transplantation?
FEATURING
William Tse
- 110 views
- February 27, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Future Directions in AML: Optimizing Doublets and Triplets to Improve Efficacy and Maintain Safety
FEATURING
Naval Daver
- 58 views
- February 15, 2024
Diagnostics & Biomarkers
SOHO Brazil 2024
Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde
FEATURING
Jeffrey Lancet
- 530 views
- July 11, 2024
- 2
Moffitt Cancer Center
Using Transplant in Patients With p53 Mutant MDS or AML
FEATURING
Hany Elmariah
- 329 views
- March 7, 2024
- 5
University of Miami Sylvester Comprehensive Cancer Center
Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis but is Actionable
FEATURING
Sangeetha Venugopal
- 185 views
- March 18, 2024
- 1
UChicago Medicine 12th International Clinical Cancer Genomics Conference
MDS and AML: Implementation of Guideline-Driven Germline Genetic Evaluation Criteria
FEATURING
Lauren Banaszak
- 399 views
- May 28, 2024
- 4
Icahn School of Medicine at Mount Sinai
BPDCN: Current and Future Directions
FEATURING
Naveen Pemmaraju
- 488 views
- May 31, 2024
- 2
SOHO Highlights: State of the Art and Next Questions
State of the Art and Next Questions: AML
FEATURING
Farhad Ravandi
- 384 views
- March 25, 2024
- 2
i3 Health
MRD Testing in Leukemias: When Negativity Is a Positive Thing
FEATURING
Noopur S. Raje
- 476 views
- March 15, 2024
- 1
Jesse Hirner
BPDCN: A Dermatologist's Perspective on Differential Diagnosis
- 1,656 views
- August 16, 2024
- 10
Rush University Medical Center
What is New in AML: Risk Classification, Germline Mutations, and Targeted Therapies
FEATURING
Ehab Atallah
- 231 views
- May 29, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Use and Interpretation of Molecular Genetics in Blood Cancer
FEATURING
Jennifer Morrissette
- 350 views
- March 4, 2024
- 2
MyCancerHaven
Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPDCN
FEATURING
Ravi Vij,
Guru Murthy
- 608 views
- August 30, 2024
- 3
MyCancerHaven
Experts Discuss How to Approach Frontline Treatment of Unfit Patients With AML
- 105 views
- May 22, 2024
Talha Badar
Challenges in the Management of TP53-Mutated AML: Potential Strategies to Improve Outcomes
- 452 views
- March 5, 2024
- 3
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Approach to MRD Monitoring in AML: Assessing Treatment Efficacy and Relapse Risk
FEATURING
Tapan Kadia
- 104 views
- September 11, 2024
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
AML: Diagnosis, Trends, and Approaches
FEATURING
Mary-Beth Percival
- 82 views
- August 14, 2024
Icahn School of Medicine at Mount Sinai
Therapeutic Targeting of RNA Splicing Factor Mutant Leukemias
FEATURING
Omar Abdel-Wahab
- 57 views
- July 2, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Acute Promyelocytic Leukemia: Risk Stratification and New Treatment Modalities
FEATURING
Suar ÇAkı Kılıç
- 83 views
- February 16, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Pediatric AML: Diagnosis and Risk Stratification
FEATURING
Nihal Karadaş
- 179 views
- February 16, 2024
Disease Overview
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
FEATURING
Robert Peter Gale
- 3,523 views
- February 26, 2024
- 19
Jesse Hirner
BPDCN: A Dermatologist's Perspective on Differential Diagnosis
- 1,656 views
- August 16, 2024
- 10
MyCancerHaven
Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPDCN
FEATURING
Ravi Vij,
Guru Murthy
- 608 views
- August 30, 2024
- 3
Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course
AML: Diagnosis, Trends, and Approaches
FEATURING
Mary-Beth Percival
- 82 views
- August 14, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Pediatric AML: Diagnosis and Risk Stratification
FEATURING
Nihal Karadaş
- 179 views
- February 16, 2024
Case Studies
Indy Hematology Review
R/R AML: Current, Emerging, and Targeted Therapies
FEATURING
Rami Komrokji
- 350 views
- April 22, 2024
- 3
Tisch Cancer Institute at Mount Sinai
Leukemia Tumor Board: 25 y/o With FLT3-TKD+ AML
FEATURING
Justine Anderson
- 87 views
- May 6, 2024
Vanderbilt University Medical Center (VUMC)
Age Limits in Stem Cell Transplants and Cell Therapy
FEATURING
Reena Jayani
- 66 views
- July 22, 2024
UNC Lineberger Comprehensive Cancer Center
Strategies for Managing Toxicities of Oral Oncolytics in Leukemia
- 57 views
- August 28, 2024
Moffitt Cancer Center
Optimal Use of Targeted Therapy for the Elderly or Unfit AML Patient
FEATURING
Onyee Chan
- 109 views
- March 5, 2024